Insight Molecular Diagnostics (IMDX) Enterprise Value (2020 - 2025)
Historic Enterprise Value for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$19.4 million.
- Insight Molecular Diagnostics' Enterprise Value fell 47144.12% to -$19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.4 million, marking a year-over-year decrease of 47144.12%. This contributed to the annual value of -$8.6 million for FY2024, which is 843.94% up from last year.
- As of Q3 2025, Insight Molecular Diagnostics' Enterprise Value stood at -$19.4 million, which was down 47144.12% from -$24.3 million recorded in Q2 2025.
- In the past 5 years, Insight Molecular Diagnostics' Enterprise Value registered a high of -$3.4 million during Q3 2024, and its lowest value of -$59.8 million during Q1 2021.
- In the last 5 years, Insight Molecular Diagnostics' Enterprise Value had a median value of -$20.4 million in 2022 and averaged -$23.7 million.
- Its Enterprise Value has fluctuated over the past 5 years, first skyrocketed by 7612.53% in 2024, then crashed by 47144.12% in 2025.
- Quarter analysis of 5 years shows Insight Molecular Diagnostics' Enterprise Value stood at -$33.9 million in 2021, then surged by 39.66% to -$20.4 million in 2022, then surged by 53.82% to -$9.4 million in 2023, then grew by 8.44% to -$8.6 million in 2024, then tumbled by 124.98% to -$19.4 million in 2025.
- Its last three reported values are -$19.4 million in Q3 2025, -$24.3 million for Q2 2025, and -$31.0 million during Q1 2025.